GregoryDore

image - 1347600903 Greg Dore
Gregory
Dore
My Contact Email
gdore@kirby.unsw.edu.au
Research field
University role
Professor and Program Head
School
The Kirby Institute
Campus
Non Campus Based
Faculty
Medicine
Phone
02 9385 0900
Contact Fax
02 9385 0876
Bio

Professor Gregory Dore is Head of the Viral Hepatitis Clinical Research ProgramKirby Institute for infection and immunity in society, The University of New South Wales and an Infectious Diseases Physician at St Vincent’s Hospital, Sydney. He has been involved in the hepatitis C sector for 15 years, in academic research, clinical, and public health policy capacities.

Professor Dore’s major research work has been in the areas of hepatitis C natural history, and therapeutic strategies. In the area of clinical research, he has led studies in acute hepatitis C, hepatitis C therapy for current injecting drug users and individuals on opiate dependency pharmacotherapy. He has published 180 peer-reviewed publications and has current research funding from Australia’s National Health and Medical Research Council (NHMRC) and the US National Institutes of Health, including a NHMRC Program Grant, Partnership Grant, CRE and CCRE.

He is the editor of the book Hepatitis C: an Expanding Perspective. In recent years, he has been awarded a NHMRC Practitioner Fellowship and the Australasian Society for Infectious Diseases (ASID) Frank Fenner Award for Advanced Research in Infectious Diseases. Professor Dore has been a leader in Australia’s public health policy response to viral hepatitis including membership of national and state advisory committees. He is immediate past President of the Australasian Society for HIV Medicine (ASHM) the peak body for HIV clinicians and increasingly involved in viral hepatitis education and training.

Professor Dore established the St Vincent’s Hospital Hepatitis Clinic in 1999 and has led development of the hepatitis C clinical service into one of Australia’s leading services. Particular focuses of the clinical service development have been treatment of people who inject drugs, people on opiate pharmacotherapy, and the integration of viral hepatitis clinical service and clinical research.